| Literature DB >> 33732240 |
Yunhan Ma1, Guoliang Yan2, Junjun Guo2, Fujun Li3, Haiping Zheng2, Chenxi Wang2, Yingyu Chen1, Yuhan Ye4, Helong Dai5,6,7, Zhongquan Qi8, Guohong Zhuang1.
Abstract
Berberine, which is a traditional Chinese medicine can inhibit tumorigenesis by inducing tumor cell apoptosis. However, the immunoregulatory of effects berberine on T cells remains poorly understood. Here, we first examined whether berberine can prolong allograft survival by regulating the recruitment and function of T cells. Using a major histocompatibility complex complete mismatch mouse heterotopic cardiac transplantation model, we found that the administration of moderate doses (5 mg/kg) of berberine significantly prolonged heart allograft survival to 19 days and elicited no obvious berberine-related toxicity. Compared to that with normal saline treatment, berberine treatment decreased alloreactive T cells in recipient splenocytes and lymph node cells. It also inhibited the activation, proliferation, and function of alloreactive T cells. Most importantly, berberine treatment protected myocardial cells by decreasing CD4+ and CD8+ T cell infiltration and by inhibiting T cell function in allografts. In vivo and in vitro assays revealed that berberine treatment eliminated alloreactive T lymphocytes via the mitochondrial apoptosis pathway, which was validated by transcriptome sequencing. Taken together, we demonstrated that berberine prolongs allograft survival by inducing apoptosis of alloreactive T cells. Thus, our study provides more evidence supporting the potential use of berberine in translational medicine.Entities:
Keywords: T cell; alloimmunity and transplantation; berberine; heart allograft survival; immunological tolerance and memory; immunoregulation; transplantation immunology
Mesh:
Substances:
Year: 2021 PMID: 33732240 PMCID: PMC7959711 DOI: 10.3389/fimmu.2021.616074
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561